11ABSTRACTObjectives: The objective of this work is to establish a bioanalytical technique for the quantification of atrasentan. The employed methodology for the detection and quantification of atrasentan in human plasma has a high degree of specificity, sensitivity, and simplicity. Methods: Shimadzu pumps were utilized in conjunction with an Autosampler Agilent Zorbax XDB C18 2.1 × 50 mm, 5 μm column employed as a stationary phase to achieve the chromatographic separation. Acetonitrile (0.1% formic acid) and 5 mM ammonium formate made up the mobile phase, which was optimized to have a 70:30% v/v ratio. Isocratic elution was employed in the experiment, with a flow rate of 0.150 mL/min. The entire cycle took 3.0 minutes, using a 10 μL injection volume. Results: The detection procedure is executed utilizing positive ion mode electrospray ionization (ESI) mass spectrometry under atmospheric pressure. For atrasentan, the precursor to product ion transitions used for quantification was m/z 511.623 to 354.15 and for the internal standard, verapamil, m/z 455.22 to 165. 02. The retention times for atrasentan and verapamil were found to be 1.68 and 0.96 minutes, respectively.Conclusion: In accordance with the recommendations of the United States Food and Drug Administration (USFDA) and EMA, it was ascertained that the remaining validation parameters remained within the specified range.
Read full abstract